{"id":"imo-2125","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reaction"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By activating TLR9, IMO-2125 induces the production of cytokines and enhances the activity of natural killer cells and dendritic cells, which can lead to an antitumor immune response.","oneSentence":"IMO-2125 is a synthetic oligonucleotide that acts as a TLR9 agonist, stimulating the innate immune system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:35:47.662Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors"}]},"trialDetails":[{"nctId":"NCT03445533","phase":"PHASE3","title":"A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma","status":"TERMINATED","sponsor":"Idera Pharmaceuticals, Inc.","startDate":"2018-05-30","conditions":"Metastatic Melanoma","enrollment":481},{"nctId":"NCT02644967","phase":"PHASE2","title":"A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Idera Pharmaceuticals, Inc.","startDate":"2015-12","conditions":"Metastatic Melanoma","enrollment":53},{"nctId":"NCT03865082","phase":"PHASE2","title":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Idera Pharmaceuticals, Inc.","startDate":"2019-10-29","conditions":"Solid Tumor","enrollment":30},{"nctId":"NCT04126876","phase":"PHASE2","title":"A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma","status":"RECRUITING","sponsor":"A.J.M. van den Eertwegh","startDate":"2020-01-22","conditions":"Malignant Melanoma","enrollment":214},{"nctId":"NCT03052205","phase":"PHASE1","title":"A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors","status":"COMPLETED","sponsor":"Idera Pharmaceuticals, Inc.","startDate":"2017-06-09","conditions":"Refractory Solid Tumors, Melanoma","enrollment":54},{"nctId":"NCT00990938","phase":"PHASE1","title":"Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients","status":"COMPLETED","sponsor":"Idera Pharmaceuticals, Inc.","startDate":"2009-09","conditions":"Hepatitis C, Treatment Naïve, Genotype 1 Patients","enrollment":63},{"nctId":"NCT00728936","phase":"PHASE1","title":"Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Idera Pharmaceuticals, Inc.","startDate":"2007-09","conditions":"Hepatitis C","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["tilsotolimod (tilso)"],"phase":"phase_2","status":"active","brandName":"IMO-2125","genericName":"IMO-2125","companyName":"Idera Pharmaceuticals, Inc.","companyId":"idera-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IMO-2125 is a synthetic oligonucleotide that acts as a TLR9 agonist, stimulating the innate immune system. Used for Advanced solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}